Can-Fite Biopharma Ltd ADR [AMEX: CANF] price surged by 5.00 percent to reach at $0.02.
A sum of 353485224 shares traded at recent session while its average daily volume was at 196.08K shares. Can-Fite Biopharma Ltd ADR shares reached a high of $0.615 and dropped to a low of $0.3801 until finishing in the latest session at $0.38.
The one-year CANF stock forecast points to a potential upside of 94.37. The average equity rating for CANF stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Can-Fite Biopharma Ltd ADR [CANF]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CANF shares is $6.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CANF stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Can-Fite Biopharma Ltd ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 11, 2017. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on October 19, 2016, representing the official price target for Can-Fite Biopharma Ltd ADR stock. Previously, the target price had yet another raise to $6, while Rodman & Renshaw analysts kept a Buy rating on CANF stock. On November 30, 2015, analysts increased their price target for CANF shares from 4 to 6.
The Price to Book ratio for the last quarter was 1.20, with the Price to Cash per share for the same quarter was set at 0.38.
CANF Stock Performance Analysis:
Can-Fite Biopharma Ltd ADR [CANF] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.89. With this latest performance, CANF shares dropped by -26.37% in over the last four-week period, additionally sinking by -63.97% over the last 6 months – not to mention a drop of -76.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CANF stock in for the last two-week period is set at 27.19, with the RSI for the last a single of trading hit 0.0496, and the three-weeks RSI is set at 0.0370 for Can-Fite Biopharma Ltd ADR [CANF]. The present Moving Average for the last 50 days of trading for this stock 0.5263, while it was recorded at 0.3741 for the last single week of trading, and 0.9954 for the last 200 days.
Can-Fite Biopharma Ltd ADR (CANF) Capital Structure & Debt Analysis
Can-Fite Biopharma Ltd ADR (CANF) Efficiency & Liquidity Metrics
Based on Can-Fite Biopharma Ltd ADR’s (CANF) latest financial statements, the Debt-to-Equity Ratio is 0.02%, indicating its reliance on debt financing relative to shareholder equity.
Can-Fite Biopharma Ltd ADR (CANF) Efficiency & Liquidity Metrics
Can-Fite Biopharma Ltd ADR [CANF] Institutonal Ownership Details
There are presently around $9.15%, or 9.15%% of CANF stock, in the hands of institutional investors. The top three institutional holders of CANF stocks are: ARMISTICE CAPITAL, LLC with ownership of 0.52 million shares, which is approximately 7.12%. MORGAN STANLEY, holding 67807.0 shares of the stock with an approximate value of $$0.17 million in CANF stocks shares; and MORGAN STANLEY, currently with $$39727.0 in CANF stock with ownership which is approximately 0.2113%.
